High/Fast Membrane Transport in Peritoneal Dialysis
High or fast membrane transport in PD means your peritoneal membrane allows solutes (like creatinine) to move rapidly between blood and dialysate, which creates three major clinical problems: poor ultrafiltration (fluid removal), increased protein losses, and higher glucose absorption.
What This Means Physiologically
The peritoneal membrane acts as a filter between your blood and the dialysis fluid. In fast transporters, this membrane is more permeable than average, measured by the peritoneal equilibration test (PET) using the 4-hour dialysate-to-plasma creatinine ratio (D/Pc) 1, 2.
Fast transport creates a clinical paradox: while solutes move quickly into the dialysate (which sounds good), glucose from the dialysate also absorbs rapidly into your bloodstream, eliminating the osmotic gradient needed for fluid removal before the dwell time is complete 3.
Three Types of Fast Transporters
The clinical significance depends on which type you have 3:
- Type 1 (Early inherent with comorbidity): Associated with inflammation and cardiovascular disease at baseline—these patients have poor outcomes regardless of dialysis modality
- Type 2 (Early inherent with large peritoneal surface): Naturally large membrane surface area but otherwise healthy
- Type 3 (Late acquired): Develops over time on PD due to membrane changes from glucose exposure and bioincompatible solutions
Types 2 and 3 have good prognosis when fluid balance is properly managed 3.
Clinical Consequences
Fast transporters face specific challenges 4, 5:
- Poor ultrafiltration: Rapid glucose absorption eliminates osmotic gradient during standard dwells
- Increased protein losses: Higher membrane permeability leads to albumin loss into dialysate
- Metabolic abnormalities: Excessive glucose absorption causes hyperglycemia and weight gain
- Protein-energy wasting: Fast transport is independently associated with malnutrition (OR: 2.6) 5
Historical vs. Contemporary Significance
The prognostic impact of fast transport has diminished substantially in modern PD practice 6. While meta-analysis from 2006 showed 77% increased mortality risk in high transporters 7, recent 2026 data demonstrates this association has become era-dependent and "less pronounced in contemporary practice" with a significant transport-by-era interaction (P=0.044) 6.
This improvement reflects better management strategies rather than changed biology 3.
Management Approach
The key is avoiding long-duration dwells that allow complete glucose absorption and fluid reabsorption 1:
For CAPD Patients:
- Switch to APD without long day dwells, OR
- Use icodextrin solution for the long nocturnal dwell (proven in RCTs to increase ultrafiltration and decrease extracellular fluid volume) 1
- Consider night-exchange devices to split the nocturnal dwell into two shorter dwells
For APD Patients:
- Shorten or eliminate the day dwell (leave patient "dry" during day), OR
- Drain and replace the day dwell midway through, OR
- Use icodextrin for the long day dwell 1
Additional Strategies:
- High-dose loop diuretics if residual kidney function exists 1
- ACE inhibitors or ARBs to preserve residual function 1
- Dietary sodium restriction
- Avoid hypertonic glucose solutions chronically (causes membrane damage) 1
Critical Caveat About Middle Molecules
If you're a fast transporter with minimal residual kidney function on APD with dry days, you need at least low-volume long-duration dwells to maintain middle-molecule clearance 2. While small-solute targets (Kt/V) may be met with short dwells, middle-molecule clearance is time-dependent and requires longer contact time 2.
Bottom Line
Fast transport is a prescription challenge, not a death sentence. Interpret PET-derived transport status as a guide for individualizing your PD prescription rather than as a fixed predictor of poor outcome 6. With APD and icodextrin, fluid balance can be controlled effectively in Types 2 and 3 fast transporters 3.